Complement activation and ADAMTS13 suppression may contribute to the characteristic pathological features in Upshaw-Schulman Syndrome

Complement activation and ADAMTS13 suppression may contribute to the characteristic pathological features in Upshaw-Schulman Syndrome - Complement activation and ADAMTS13 suppression in USS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000027482

Enrollment

Registered

2017-06-01

Start date

2017-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Upshaw-Schulman syndrome

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Severe deficient ADAMTS13 activity (<10%), negative for ADAMTS13 inhibitor and mutations in the ADAMTS13 gene

Exclusion criteria

Exclusion criteria: Transplanted kidney

Design outcomes

Primary

Measure	Time frame
Immunohistochemistry of ADAMTS13, C4d and C5b-9 of Upshaw-Schulman syndrome renal biopsies	—

Countries

Japan

Contacts

Public ContactHiroe Itami

Nara medical university Department of diagnostic pathology

hritami@naramed-u.ac.jp.0744-29-8910

Outcome results